In patent litigation between branded and generic manufacturers of canine flea & tick products, CRA was asked to assess irreparable harm. CRA examined effects from the entry and ongoing sales of the generic products, business losses suffered by the branded manufacturer and whether they could be attributed to the sale of the generic products, the influence of new channels, such as the internet, and the impact of newer, more effective classes of parasiticides. CRA submitted a declaration on irreparable harm.
CRA recognized in Chambers 2026 for litigation support and crisis & risk management
Charles River Associates has been recognized in the 2026 Chambers Litigation Support and Crisis & Risk Management Guides, including a Band 1 global ranking...